These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial.
    Author: Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX.
    Journal: EuroIntervention; 2011 May; 7 Suppl K():K61-5. PubMed ID: 22027730.
    Abstract:
    AIMS: Percutaneous coronary interventions for bifurcation lesions are often complex and associated with an unsatisfactory result. The aim of this first-in-man, observational study was to investigate the efficacy and safety of a paclitaxel-eluting balloon in these lesions. METHODS AND RESULTS: Twenty-eight patients presenting significant coronary bifurcational lesions of the left coronary artery were studied. The main branch (MB) and the side branch (SB) were dilated with a drug-eluting balloon (DEB; SeQuent Please balloon catheter , 3 µg paclitaxel/mm2 balloon surface). An open-cell bare-metal stent (BMS; Coroflex) was then deployed in the MB. Only if the SB had a TIMI flow <III and/or a residual stenosis of ≥ 50%, a BMS was implanted in the SB. The procedure was successful in all patients. At nine months, the late lumen loss (LLL) in the MB was 0.38 ± 0.46 mm and 0.21 ± 0.48 mm in the SB resulting in an MLD of 2.2 ± 0.60 mm in the MB and 1.7 ± 0.44 mm in the SB. Three patients had angiographic restenosis and in one a target lesion revascularisation (TLR) was performed. Two patients experienced a late stent thrombosis at six and eight months. No patient died. CONCLUSIONS: Percutaneous treatment of bifurcation lesions with a drug-eluting balloon resulted in a procedural success of 100%. Follow-up angiography at nine months showed DES-like results in MB and SB. However, when the DEB was used in combination with a BMS (MB), the possibility of late stent thrombosis cannot be ruled out.
    [Abstract] [Full Text] [Related] [New Search]